Takeda Pharmaceutical Company faced several challenges, including lawsuits over its diabetes drug Actos and a failed merger with Shire. The company has been focusing on restructuring and developing new drugs.
Takeda, a Japan-based global pharmaceutical company, has undergone significant changes and faced various challenges in recent years. One of the most notable issues was the legal trouble surrounding its diabetes drug, Actos (pioglitazone), which was linked to an increased risk of bladder cancer. This resulted in numerous lawsuits and substantial financial settlements.
In an effort to diversify and strengthen its global presence, Takeda attempted a major acquisition of the Ireland-based pharmaceutical company Shire in 2018. However, this deal faced several hurdles and was met with mixed reactions from shareholders due to concerns over the debt Takeda would incur to finance the acquisition. Despite the challenges, the acquisition was eventually completed, making it one of the largest overseas purchases by a Japanese company.
As part of its ongoing transformation, Takeda has been focusing on restructuring its business to prioritize research and development in key therapeutic areas, such as oncology, gastroenterology, neuroscience, and rare diseases. The company has been selling non-core assets to streamline operations and reduce debt. Additionally, Takeda has been investing in the development of new drugs and therapies, aiming to bring innovative treatments to market and improve its financial performance.
The company’s efforts to adapt to the changing pharmaceutical landscape and its commitment to innovation suggest a proactive approach to overcoming the challenges it has faced. Takeda continues to be a significant player in the global pharmaceutical industry, with a strong focus on growth and patient-centric healthcare solutions.